Evaluation of the Toxicity and Outcomes of the Combination of Midostaurin and CLAG-M in Patients With FLT3-Mutated Acute Myeloid Leukemia (AML): A Multicenter Retrospective Analysis
Annals of Pharmacotherapy · 2025
DOI: 10.1177/10600280241305608 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Annals of Pharmacotherapy, 2025. Verfasst von Ashley Chen und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, UW Medicine, Fred Hutchinson Cancer Center, Seattle, WA, USA. Hauptthemen laut MEDLINE: Leukemia, Myeloid, Acute, Staurosporine, fms-Like Tyrosine Kinase 3, Antineoplastic Combined Chemotherapy Protocols. Die Arbeit nennt 26 Literaturangaben.
Abstract (Originalsprache)
Background
Addition of midostaurin to standard “7+3” (cytarabine and anthracycline) significantly prolongs overall and event-free survival. At University of Washington/Fred Hutchinson Cancer Center (UW/FHCC), the standard regimen for newly diagnosed (ND) and relapsed/refractory (R/R) AML is cladribine, high-dose cytarabine, GCSF, and mitoxantrone (CLAG-M); midostaurin is added if FLT3-mutated. There is limited data on the use of FLT3-inhibitors with high-dose cytarabine regimens in AML.
Objective
This study aimed to evaluate the safety and efficacy of the combination of midostaurin with CLAG-M versus midostaurin plus 7+3 in FLT3-mutated AML patients.
Methods
This is a retrospective, multicenter review including FLT3-mutated AML patients undergoing (re)induction chemotherapy with either CLAG-M or 7+3 at UW/FHCC, Oregon Health & Science University, and Swedish Cancer Institute. The primary outcome was incidence of adverse events. Secondary outcomes included disease response per ELN2017 criteria and 28-day mortality. Excluded were patients on clinical trials or who started midostaurin 30 days after chemotherapy.
Results
Eighty patients treated from September 2016 to December 2023 were included; 36 patients received CLAG-M, and 44 patients 7+3. Baseline characteristics were similar across all institutions. Adverse event rates were similar between the 2 cohorts, except diarrhea and bleeding which were more common in the 7+3 cohort. The rate of complete remission (CR) plus CR with incomplete blood count recovery did not significantly differ between the 2 cohorts: CLAG-M, 86% versus 7+3, 70% ( P = 0.11). Conclusion & relevance: The toxicity profile of CLAG-M combined with midostaurin is comparable with the combination of 7+3 with midostaurin, and induces high remissions rates in adults with FLT3-mutated AML.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacy, UW Medicine, Fred Hutchinson Cancer Center, Seattle, WA, USA.
- Department of Hematologic Malignancies, Fred Hutchinson Cancer Center, Seattle, WA, USA.
- Department of Statistics, UW Medicine, Seattle, WA, USA.
- Department of Pharmacy, Oregon Health & Science University, Portland, OR, USA.
- Swedish Cancer Institute, Seattle, WA, USA.
ORCID-Profile: Ashley Chen, Grace Baek, Jack Rasmussen
Zitieren
APA
Chen, A., Baek, G., Russell, K., Shaw, C., Othus, M., Cohen, J., Palmer, S., Rasmussen, J., Bubalo, J., Tsomo, T., Schwarz, T., Namburi, S., & Halpern, A. (2025). Evaluation of the Toxicity and Outcomes of the Combination of Midostaurin and CLAG-M in Patients With FLT3-Mutated Acute Myeloid Leukemia (AML): A Multicenter Retrospective Analysis. Annals of Pharmacotherapy. https://doi.org/10.1177/10600280241305608
Vancouver
Chen A, Baek G, Russell K, Shaw C, Othus M, Cohen J, et al. Evaluation of the Toxicity and Outcomes of the Combination of Midostaurin and CLAG-M in Patients With FLT3-Mutated Acute Myeloid Leukemia (AML): A Multicenter Retrospective Analysis. Annals of Pharmacotherapy. 2025. doi:10.1177/10600280241305608
BibTeX
@article{Chen2025,
author = {Chen, Ashley and Baek, Grace and Russell, Kathryn and Shaw, Carole and Othus, Megan and Cohen, Jonathan and Palmer, Shannon and Rasmussen, Jack and Bubalo, Joseph and Tsomo, Tenzin and Schwarz, Tenley and Namburi, Swathi and Halpern, Anna},
title = {Evaluation of the Toxicity and Outcomes of the Combination of Midostaurin and CLAG-M in Patients With FLT3-Mutated Acute Myeloid Leukemia (AML): A Multicenter Retrospective Analysis},
journal = {Annals of Pharmacotherapy},
year = {2025},
doi = {10.1177/10600280241305608}
}
EUVIMED